Deal snapshot: Tocagen, Forte Biosciences Close Merger to Accelerate Inflammatory Skin Disease Treatment.

MANews-(C)2009-2020

California-based gene therapy company Tocagen Inc. (NASDAQ: TOCA) has closed a merger with California-based biopharmaceutical company and Forte Biosciences, Inc., in an all-stock transaction focussed on advancing Forte's clinical programme in atopic dermatitis, the company said.

The combined company is expected to operate under the name Forte Biosciences and trade on the NASDAQ Capital Market under the...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT